A detailed history of Awm Investment Company, Inc. transactions in Oncocyte Corp stock. As of the latest transaction made, Awm Investment Company, Inc. holds 1,097,175 shares of OCX stock, worth $3.12 Million. This represents 0.5% of its overall portfolio holdings.

Number of Shares
1,097,175
Previous 754,286 45.46%
Holding current value
$3.12 Million
Previous $2.21 Million 46.43%
% of portfolio
0.5%
Previous 0.33%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$2.44 - $3.07 $836,649 - $1.05 Million
342,889 Added 45.46%
1,097,175 $3.24 Million
Q4 2023

Feb 14, 2024

BUY
$2.08 - $4.26 $72,808 - $149,117
35,004 Added 4.87%
754,286 $1.89 Million
Q3 2023

Nov 14, 2023

SELL
$0.2 - $4.28 $2.69 Million - $57.6 Million
-13,466,382 Reduced 94.93%
719,282 $2.24 Million
Q2 2023

Aug 11, 2023

BUY
$0.2 - $0.35 $1.48 Million - $2.59 Million
7,412,613 Added 109.44%
14,185,664 $3.26 Million
Q1 2023

May 12, 2023

SELL
$0.2 - $0.49 $96,234 - $235,773
-481,171 Reduced 6.63%
6,773,051 $2.37 Million
Q4 2022

Feb 14, 2023

SELL
$0.25 - $15.6 $123,083 - $7.68 Million
-492,335 Reduced 6.36%
7,254,222 $2.32 Million
Q2 2022

Aug 12, 2022

BUY
$0.86 - $1.53 $6.45 Million - $11.5 Million
7,504,690 Added 3102.82%
7,746,557 $6.97 Million
Q4 2021

Feb 14, 2022

SELL
$2.04 - $3.59 $969,271 - $1.71 Million
-475,133 Reduced 66.27%
241,867 $525,000
Q3 2021

Nov 15, 2021

BUY
$3.53 - $5.89 $176,500 - $294,500
50,000 Added 7.5%
717,000 $2.55 Million
Q2 2021

Aug 13, 2021

SELL
$3.77 - $6.0 $312,910 - $498,000
-83,000 Reduced 11.07%
667,000 $3.83 Million
Q1 2021

May 13, 2021

BUY
$2.39 - $6.5 $1.79 Million - $4.88 Million
750,000 New
750,000 $3.89 Million

Others Institutions Holding OCX

About Oncocyte Corp


  • Ticker OCX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 118,609,000
  • Market Cap $337M
  • Description
  • OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay....
More about OCX
Track This Portfolio

Track Awm Investment Company, Inc. Portfolio

Follow Awm Investment Company, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Awm Investment Company, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Awm Investment Company, Inc. with notifications on news.